The list of potential drugs against the Covid-19 continues to shrink : after hydroxychloroquine, clinical trials by european Solidarity and Discovery have also abandoned the treatment and lopinavir/ritonavir, was deemed ineffective and suspected adverse effects.
After this decision, these two trials will now focus more than on a single drug, the remdesivir, just get a placing on the market conditional within the european Union.